

March 25, 2024

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort
Mumbai – 400 001

The Manager- Listing

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G - Block
Bandra –Kurla Complex, Bandra (E)
Mumbai – 400 051

Dear Sir(s),

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Appointment of Senior Management Personnel

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company have approved the appointment of Mr. Vinay Sharma as Business Unit Head - Rare Disease unit with effect from July 1, 2024.

In this regard, please find the details as required under the SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 attached herewith as **Annexure – A**.

Kindly take the above information on record.

For AstraZeneca Pharma India Limited

Manasa. R
Company Secretary

Annexure - A

Sl. No	Particulars	Details
1	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment of Mr. Vinay Sharma as Business Unit Head - Rare Disease Business Unit
2	Date of appointment/ cessation (as applicable) and term of appointment	Effective July 1, 2024 Term of appointment – Full – time employment
3	Brief Profile	<p>Mr. Vinay Sharma is a Post-Graduate in Marketing Management and Business Administration with over 23 years of rich industry experience. He joined AstraZeneca India in 2013 as Marketing Manager Diabetes. Over the last decade, years, he has held multiple sales, marketing, patient advocacy lead and leadership positions in AstraZeneca India and other international markets. He has been instrumental in leading the best-in-class launch of Forxiga in India.</p> <p>Currently, Mr. Vinay Sharma is a part of the Philippines Country Leadership Team as Business Unit Head Respiratory & Immunology.</p>
4	Disclosure of relationships between directors	Not Applicable